NBRV Nabriva Therapeutics Plc

Nabriva Therapeutics AG is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics.

As of 12/03/2021     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Ireland
Country of incorporation:  Ireland
IPO date:  09/18/2015
Outstanding shares:  56,719,737
Average volume:  1,065,702
Market cap:   $41,859,166
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    62957M104
ISIN:        IE00BYQMW233
Sedol:      BYQMW23
Valuation   (See tab for details)
PE ratio:   -0.74
PB ratio:   0.61
PS ratio:   2.29
Return on equity:   -57.52%
Net income %:   -198.83%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy